A New Beacon in Oncology: Precision Targeting with First-in-Class therapies

- ✓ Highly selective target in 17+ solid tumors, zero expression in normal tissue
- ✓ Lead asset YB-811 addresses blockbuster indications with >$10B market potential
- ✓ Clear exit strategy: 2028 via IPO, licensing ($800M–$1.2B), or spinouts
- ✓ Projected ROI: 20–40x with long-term upside from multiple follow-on indications

Ymmunobio: Precision Oncology via NPTXR-Targeted Conjugates

Transforming solid tumor treatment with novel, highly selective compounds

The Problem

- Existing target antigens also found in healthy tissues → off-target toxicity
- Crowded space → few tumor-specific, druggable targets remaining

Our Solution

- First-in-class program targeting NPTXR, a tumor-selective antigen
- Expressed in 17+ solid tumors
- Undetectable in healthy tissues
- Preclinical data show potent efficacy and clean safety profile

Market Opportunity

- Estimated Target Addressable Market (TAM) > $10B (with ADC)
- Addresses unmet needs in CRC, GC, sq NSCLC, TNBC, Pancreatic Cancer & more
- IP-protected first mover in NPTXR targeting

Why Now

- Growing demand for safer, tumor-specific compounds
- IND-enabling studies in progress; data-readiness in 2026
- Targeted therapy M&A activities surging

2025 Funding Goal

$ 15M

- IND-enabling & Phase I readiness
- Toxicology studies
- Regulatory preparation

2026 Funding Goal

$ 85M

- PoC in Humans: Phase I Dose Escalation & Expansion Cohort

Exit Path

- Licensing Post-PoC
- IPO & Spinouts

Strategic Opportunity Across High-Value Oncology Markets



- Colorectal, sq NSCLC, and gastric emerge as top opportunities (high incidence, strong NPTXR expression, and large TAM);
- Broad tumor-selective potential of our program with minimal off-target risk.

The strategic potential of NPTXR-targeted therapies: **global incidence (X-axis)**, **NPTXR prevalence (Y-axis)**, and **target addressable market (bubble size)** for five major solid tumor indications.

Exit Scenarios & Investor ROI

Scenario 1
Licensing Post – PoC

- **Upfront**: US$ 80 – 120M,
- **Milestones**: US$ 500 – 700M,
- **Royalty**: 10-12% on all solid tumors;
- Increasing royalties as additional indications are launched

Scenario 2
IPO & Spinouts

- IPO value US$ 800M – 1.2B with YB-811 first-in-class ADC.
- Future subsidiaries:
  - Ymmuno-T (CAR-T),
  - Ymmuno-B (BiTCE),
  - Ymmuno-R (Radiopharmaceuticals)
- Each unit to be independently financed or partnered post-IPO



Investor ROI

- Entry valuation: US$ 20 – 25M
- Exit: US$ 800 – 1.2B
- **ROI: 20 – 40x**

Ymmunobio Executive Summary

THE COMPANY & TEAM

- Ymmunobio was founded in 2021 by **two experienced drug developers**
- **IP acquisition for antibody & strong IP around new tumor target** from Nagoya University, Japan
- **Experienced team supported by leading scientific advisors** (academic, clinical development, CMC, BD, legal)

SCIENCE

- **First in class Target:** detected in **+17 tumors, not in healthy tissue, prevalence < 98%, 100% tumor cells +!**

THERANOSTICS PLATFORM

- Fully humanized antibody targeting NPTXR as basis for **new treatment options**: YB-800
  - **YB-811:** dual payload; 3rd generation linker ADC; ADR=8
  - **YB-820 & YB-821:** Bi-specific T-Cell engager (aCD3) in support with Oncode Accelerator***
  - **YB-830 & YB-831:** (^{177}Lu,^{161}Tb), RPT development in collaboration with PSI* funded by Innosuisse**
  - **YB-840: CAR-T cell treatment** in solid tumors
  - **Liquid biopsy diagnostic test -** development with partner **EVIIVE AG**

IP

- **Ymmunobio owns IP:** MoU US '23 & '24, JPN '24; CoM submitted EP '24, PCT '25, US/JPN/CN '26

MARKET TARGET

- **Gastro-intestinal, Genitourinary, Lung and Breast cancer**

COMPETITORS

- **No competitor** on NPTXR; **Tumor Beacon is "locked-in"** by both patents

FUNDRAISING

- Raised **USD 2.31 M** (founders (USD 1.05M), private investors, CLA: USD 617K
- Innosuisse** **Grant** (non-dilutive) awarded: **USD 525'000** for developing Radiopharmaceuticals with PSI*
- **Short term IND readiness: USD 15 M, Long term PoC in humans: USD 85 M**

EXIT SCENARIOS

- **Major: After PoC in Humans; Minor: IND approval**

* PSI = Paul Scherrer Institute, Switzerland; ** Innosuisse = Swiss Government Innovation Agency; *** Oncode Accelerator = Dutch Government Fund

Therapeutic Modality Pipeline

hmAb - ADC – Radionuclide – BiTE – CAR-T

Partnerships

YUMAB

Immunwork

Oncode Accelerator Foundation

Universiteit Utrecht

Innovation project supported by Schweizerische Eidgenossenschaft Confédération suisse Confederazione Svizzera Confederaziun svizra Swiss Confederation Innosuisse – Swiss Innovation Agency

PSI

ProMab Biotechnologies, Inc. Custom Antibodies











Programs	**hmAb* YB-800**	**ADC** YB-811**	**BiTCE*** YB-820/821**	**Radionuclide YB-830/831/(832 - imaging)**	**CAR-T**** YB-840**
Indications	Basis	CRC, Gastric, Breast	sq NSCLC	CRC, TNBC, Bladder	Multiple Tumors
Status	**Research tool** (FACS, ELISA, IHC, WB,…)	**Preclinical IND end 2026**	**Lead Optimization**	**Lead Candidate Selection Therapeutic Diagnostic** (Imaging)	**Discovery**

*hmAb: humanized monoclonal antibody; **ADC: Antibody Drug Conjugate; ***BiTE: Bi-specific T-Cell Engager; ****CAR-T: Chimeric Antigen Receptor T-Cell Therapy
Yumab: Yumab GmbH, Germany; TE Meds: TE Meds, Taiwan; PSI: Paul-Scherrer-Institute, Switzerland; Oncode Accelerator, Netherlands; ProMab Biotechnologies, USA

Development Plan for YB-800 lead ADC until PoC in Humans



In Vivo results of both ADCs compared to vehicle and YB-800



Similar statistically-significant pronounced effect of YB800-ADCs on T1016 tumor growth (~90% TGI)

Conclusions from in vivo study

- **Tolerability**
  - **No** treatment-related animal **death**
  - **No** treatment-related animal body **weigh loss**, nor change in animal behavior
  - **Macroscopic observation of main organs** (at necropsy) including general appearance, liver (size and color), spleen (size and color), lung, GI tract, fat stores, heart and kidney: **no noticeable changes observed**
- **Efficacy**
  - Pronounced anti-tumor efficacy (~90% TGI) upon treatment with YB800MMAF or YB800MMAF-Exatecan.

YB-800: Ymmunobio is the exclusive Patent owner

- Medical and Diagnostic Use (Method of Use - MoU)

- Composition of Matter (CoM)

NPTXR target ”locked in”; patents prevent competitors from working on NPTXR; verified by 2nd patent law firm

YB-800 patents:

1st : Therapeutic agent targeted to receptor protein, test agent, antibody that binds to receptor protein, and screening method for molecularly targeted drugs.

2nd : A novel antibody binding specifically to NPTXR and use thereof.

Claims:	Medical use for defined cancers and Use as a diagnostic tool (1st patent) Composition of matter for optimized antibody (2nd patent)
Int. scope:	1st patent pending in EP; Granted: **US** (Oct 2023 & Sep 2024), **JPN** Dec 2024 2nd patent pending, as EP submitted in 2024; PCT in 2025; US, JPN & CN to be submitted in 2026
Int. filing date:	25.01.2019 (1st patent) 15.04.2024 (2nd patent)

Experienced Executive Team

Dr. Peter Schiemann, PhD

CEO, Chairman & Co-Founder

Entrepreneur with over 30 years Experience in Pharma

Dr. Michel Janicot, PhD

Chief Development Officer

Over 30 years in Drug Development and preclinical expert in oncology

Selena Blackmore

Director Business Operation

Over 20 years Experience in Life Sciences

Estelle Chao, MBA

Head Business Development

Over 20 years experience in drug development

Martin E. Zuzulo, MSc

Chief Operations Officer

Over 30 years Experience in Life Sciences

Christian Germa, MSc

Chief Finance Officer

Over 25 years experience in finance

BEST STARTUP CATEGORY
PRIX GALIEN USA
NOMINEE 2024

Ymmunobio
3rd Place

Grant recipient of
Innosuisse
Swiss Innovation Agency

Ymmunobio

Thank you!

PETER SCHIEMANN, PHD
CEO & Chairman

peter.schiemann@ymmuno.bio

+41-76-378 59 30
+1-908-294-1212

Disclaimer

All the information contained in this document is provided for information purposes only and does not constitute, and should not be viewed as, an offer, invitation or solicitation to take any action, or as the sole basis for any investment decision or a recommendation to buy the company's securities.

The contents of this document were carefully prepared and researched. Notwithstanding this, the company makes no guarantee that the information presented here is correct, complete or current.

Furthermore, the company accepts no liability for any direct or indirect losses, liability claims, costs, demands, expenses or damages, whatever their nature, arising from or connected with the use of all or part of the information contained in this document.

All statements other than statements of scientific facts contained in this document are forward-looking statements or opinions. Such forward-looking statements and opinions involve known and unknown risks, uncertainties, and other factors, which can result in the actual results, financial situation, evolution or performance of the company differing substantially from that directly or indirectly referred to in those forward-looking statements or opinions. Given these uncertainties, potential investors should not rely on these forward-looking statements and opinions.

The company cannot guarantee that the opinions and forward-looking statements contained in this document prove to be correct.

The company assumes no responsibility or duty to update these forward-looking statements publicly or to adapt them to reflect future events, developments or expectations.